

Proprotein Convertase Subtilisin and Kexin Type 9-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/P4DD2AEB2C0MEN.html>

Date: May 2018

Pages: 141

Price: US\$ 3,480.00 (Single User License)

ID: P4DD2AEB2C0MEN

Abstracts

Report Summary

Proprotein Convertase Subtilisin and Kexin Type 9-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Proprotein Convertase Subtilisin and Kexin Type 9 industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Proprotein Convertase Subtilisin and Kexin Type 9 2013-2017, and development forecast 2018-2023

Main market players of Proprotein Convertase Subtilisin and Kexin Type 9 in Europe, with company and product introduction, position in the Proprotein Convertase Subtilisin and Kexin Type 9 market

Market status and development trend of Proprotein Convertase Subtilisin and Kexin Type 9 by types and applications

Cost and profit status of Proprotein Convertase Subtilisin and Kexin Type 9, and marketing status

Market growth drivers and challenges

The report segments the Europe Proprotein Convertase Subtilisin and Kexin Type 9 market as:

Europe Proprotein Convertase Subtilisin and Kexin Type 9 Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany
United Kingdom
France
Italy
Spain
Benelux
Russia

Europe Proprotein Convertase Subtilisin and Kexin Type 9 Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others

Europe Proprotein Convertase Subtilisin and Kexin Type 9 Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Cardiovascular Disease
Homozygous Familial Hypercholesterolemia
Liver Disease
Metabolic Syndrome
Others

Europe Proprotein Convertase Subtilisin and Kexin Type 9 Market: Players Segment Analysis (Company and Product introduction, Proprotein Convertase Subtilisin and Kexin Type 9 Sales Volume, Revenue, Price and Gross Margin):

AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE

1.1 Definition of Proprotein Convertase Subtilisin and Kexin Type 9 in This Report

1.2 Commercial Types of Proprotein Convertase Subtilisin and Kexin Type

1.2.1 SX-PCK9

1.2.2 O-304

1.2.3 K-312

1.2.4 BLSM-201

1.2.5 DCRPCSK-9

1.2.6 Others

1.3 Downstream Application of Proprotein Convertase Subtilisin and Kexin Type

1.3.1 Cardiovascular Disease

1.3.2 Homozugous Familial Hyperchalesterolemia

1.3.3 Liver Disease

1.3.4 Metabolic Syndrome

1.3.5 Others

1.4 Development History of Proprotein Convertase Subtilisin and Kexin Type

1.5 Market Status and Trend of Proprotein Convertase Subtilisin and Kexin Type 9
2013-2023

1.5.1 EMEA Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and
Trend 2013-2023

1.5.2 Regional Proprotein Convertase Subtilisin and Kexin Type 9 Market Status and
Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA
2013-2017

2.2 Consumption Market of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA
by Regions

2.2.1 Consumption Volume of Proprotein Convertase Subtilisin and Kexin Type 9 in
EMEA by Regions

2.2.2 Revenue of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by
Regions

2.3 Market Analysis of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by
Regions

2.3.1 Market Analysis of Proprotein Convertase Subtilisin and Kexin Type 9 in Europe 2013-2017

2.3.2 Market Analysis of Proprotein Convertase Subtilisin and Kexin Type 9 in Middle East 2013-2017

2.3.3 Market Analysis of Proprotein Convertase Subtilisin and Kexin Type 9 in Africa 2013-2017

2.4 Market Development Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA 2018-2023

2.4.1 Market Development Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA 2018-2023

2.4.2 Market Development Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Types

3.1.2 Revenue of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Downstream Industry

4.2 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry in Major Countries

4.2.1 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry in Europe

4.2.2 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by Downstream Industry in Middle East

4.2.3 Demand Volume of Proprotein Convertase Subtilisin and Kexin Type 9 by

Downstream Industry in Africa

4.3 Market Forecast of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE

5.1 EMEA Economy Situation and Trend Overview

5.2 Proprotein Convertase Subtilisin and Kexin Type 9 Downstream Industry Situation and Trend Overview

CHAPTER 6 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Major Players

6.2 Revenue of Proprotein Convertase Subtilisin and Kexin Type 9 in EMEA by Major Players

6.3 Basic Information of Proprotein Convertase Subtilisin and Kexin Type 9 by Major Players

6.3.1 Headquarters Location and Established Time of Proprotein Convertase Subtilisin and Kexin Type 9 Major Players

6.3.2 Employees and Revenue Level of Proprotein Convertase Subtilisin and Kexin Type 9 Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE 9 MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AFFiRiS AG

7.1.1 Company profile

7.1.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product

7.1.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of AFFiRiS AG

7.2 Betagenon AB

7.2.1 Company profile

- 7.2.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
- 7.2.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Betagenon AB
- 7.3 Bioleaders Corp
 - 7.3.1 Company profile
 - 7.3.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.3.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Bioleaders Corp
- 7.4 BioLingus AG
 - 7.4.1 Company profile
 - 7.4.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.4.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of BioLingus AG
- 7.5 Catabasis Pharmaceuticals Inc
 - 7.5.1 Company profile
 - 7.5.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.5.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Catabasis Pharmaceuticals Inc
- 7.6 Dicerna Pharmaceuticals Inc
 - 7.6.1 Company profile
 - 7.6.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.6.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals Inc
- 7.7 Eli Lilly and Co
 - 7.7.1 Company profile
 - 7.7.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.7.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Eli Lilly and Co
- 7.8 Ensemble Therapeutics Corp
 - 7.8.1 Company profile
 - 7.8.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.8.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Ensemble Therapeutics Corp
- 7.9 Kowa Co Ltd
 - 7.9.1 Company profile
 - 7.9.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.9.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Kowa Co Ltd
- 7.10 Novartis AG

- 7.10.1 Company profile
- 7.10.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
- 7.10.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.11 Pfizer Inc
 - 7.11.1 Company profile
 - 7.11.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.11.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Pfizer Inc
- 7.12 Regeneron Pharmaceuticals Inc
 - 7.12.1 Company profile
 - 7.12.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.12.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc
- 7.13 Serometrix LLC
 - 7.13.1 Company profile
 - 7.13.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.13.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Serometrix LLC
- 7.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
 - 7.14.1 Company profile
 - 7.14.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.14.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- 7.15 The Medicines Company
 - 7.15.1 Company profile
 - 7.15.2 Representative Proprotein Convertase Subtilisin and Kexin Type 9 Product
 - 7.15.3 Proprotein Convertase Subtilisin and Kexin Type 9 Sales, Revenue, Price and Gross Margin of The Medicines Company

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE

- 8.1 Industry Chain of Proprotein Convertase Subtilisin and Kexin Type
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE

- 9.1 Cost Structure Analysis of Proprotein Convertase Subtilisin and Kexin Type
- 9.2 Raw Materials Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
- 9.3 Labor Cost Analysis of Proprotein Convertase Subtilisin and Kexin Type
- 9.4 Manufacturing Expenses Analysis of Proprotein Convertase Subtilisin and Kexin Type

CHAPTER 10 MARKETING STATUS ANALYSIS OF PROPROTEIN CONVERTASE SUBTILISIN AND KEXIN TYPE

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Proprotein Convertase Subtilisin and Kexin Type 9-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/P4DD2AEB2C0MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4DD2AEB2C0MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

